Results 131 to 140 of about 26,125 (257)

Ivonescimab and other anti-programmed death-1/ligand 1 (PD-(L)1)/vascular endothelial growth factor (VEGF) bispecific antibodies: progress and prospects in cancer therapy. [PDF]

Antib Ther
Dong C, Wang X.
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives. [PDF]

Front Immunol
Muthughavi K, Khokhar M, Jha HC, Pandey RK.   +3 more
europepmc   +1 more source

Seventh Åland Island Meeting on von Willebrand Disease

Haemophilia, EarlyView.
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila, Ruben Bierings, Nathan T. Connell, Fernando F. Corrales‐Medina, Augusto B. Federici, Veronica H. Flood, Floor Heubel‐Moenen, Jill M. Johnsen, Geoffrey Kuppens, Davide Matino, Carolyn Millar, Ingmar Schoen, Anish Sharda, Robert F. Sidonio Jr, Alok Srivastava, Timea Szanto, Angela C. Weyand, Erik Berntorp   +17 more
wiley   +1 more source

C-type lectin domain family 5 member A-mediated activation of macrophages via a bispecific antibody enhances anti-HER2 therapy. [PDF]

J Immunother Cancer
Hou L, Jiao D, Dai H, Zhang J, Wang L, Gong X, Qi C, Guo X, Liu Z.   +8 more
europepmc   +1 more source

Weight‐Bearing Lunge Test in Young Patients With Haemophilia and Limited Joint Damage: Reliability and Functional Associations for Ankle Assessment

Haemophilia, EarlyView.
ABSTRACT Introduction Performance‐based measures are essential for detecting early musculoskeletal functional limitations in patients with haemophilia (PwH). The Weight‐Bearing Lunge Test (WBLT) assesses ankle dorsiflexion mobility, but its psychometric properties in PwH remain unclear.
Firat Tan, Selin Aytac, Adalet Elcin Yildiz, Hande Guney Deniz   +3 more
wiley   +1 more source

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis. [PDF]

Ann Hematol
Li X, Liao J, Liu S, Mo X, Wang B.
europepmc   +1 more source

Use of the Multidimensional Haemophilia Pain Questionnaire (MHPQ) in Patients With Severe Haemophilia A Treated With Emicizumab: A Pilot Cross‐Sectional, Single‐Centre Study

Haemophilia, EarlyView.
ABSTRACT Background Despite effective bleed prevention with Emicizumab, pain remains a relevant clinical burden in adults with severe haemophilia A (sHA). A multidimensional assessment is needed to better characterize contemporary haemophilia‐related pain.
Ilenia Lorenza Calcaterra, Sofia Donnarumma, Guido D'Errico, Carmine De Luca, Chiara Caputo, Paola Ciciola, Ernesto Cimino, Matteo Di Minno   +7 more
wiley   +1 more source

Vascular Endothelial Growth Factor/Angiopoietin-2 Bispecific Antibody-Induced Vascular Normalization: From Basic Mechanisms to Therapeutic Applications in Breast Cancer. [PDF]

Immun Inflamm Dis
Li M, Han F, Ling S, Su X, Zhao Y, Lv S, Zhang X.   +6 more
europepmc   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source